文献速递血栓与止血

在3期XTEND-1研究中,使用Efanesoctocog Alfa治疗既往接受过治疗的严重A型血友病患者的出血事件

Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study.
PubMed 文献 · Am J Hematol · 2025-02-10

XTEND-1研究的事后分析评估了每周一次Efanesoctocog Alfa(50 IU/kg)预防治疗或按需治疗后转为预防治疗对严重A型血友病经治患者出血事件的疗效。159例参与者共报告422次出血事件,其中362次接受治疗,97%经单次注射缓解,95%可评估注射的应答评为优/良,Arm A预防治疗的中位总体年出血率为0.00。

要点

  • Arm A预防治疗中75例无出血事件,中位总体年出血率为0.00(IQR 0.00-1.04)。
  • 97%(350/362)的治疗出血事件经单次注射缓解,无事件需超过3次注射。
  • 95%可评估注射的应答评为优/良,每次出血事件中位总剂量为50.9 IU/kg。

核心结论

  • 每周一次Efanesoctocog Alfa(50 IU/kg)为严重A型血友病经治患者提供高效的出血保护和出血事件治疗。

研究设计与样本

  • XTEND-1(NCT04161495)3期研究的事后分析,纳入既往接受过治疗的≥12岁严重A型血友病患者,接受50 IU/kg Efanesoctocog Alfa每周一次预防治疗(Arm A)或按需治疗后转为每周一次预防治疗(Arm B)。

主要发现

  • XTEND-1期间159例参与者共报告422次出血事件,其中362次接受治疗。
  • 大多数治疗出血事件(74%;n=268)发生在Arm B按需治疗期间,其中197次(74%)为自发性。
  • Arm A中75例无出血事件,Arm B所有参与者在按需治疗期间均至少有1次出血事件。
  • 大多数参与者(n=107,81%)无治疗的自发性出血事件,Arm A中位总体年出血率为0.00(IQR 0.00-1.04)。
  • 97%(350/362)的治疗出血事件经单次注射缓解,无出血事件需要超过3次注射,95%可评估注射的应答评为优/良,每次出血事件中位总剂量为50.9 IU/kg。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite therapeutic advances, people with hemophilia experience bleeds. These may be life-threatening, result in permanent joint damage, chronic pain, difficulties with mobility/daily activities, and impact quality of life. In the XTEND-1 study (NCT04161495), once-weekly efanesoctocog alfa (50 IU/kg) prophylaxis provided highly effective bleed prevention and high-sustained factor levels for most of the week and was well-tolerated. We report post hoc analysis of bleeding episodes and their treatment in previously treated patients (≥ 12 years old). Participants received 50 IU/kg efanesoctocog alfa either as once-weekly prophylaxis (Arm A) or on-demand followed by once-weekly prophylaxis (Arm B) in XTEND-1. Endpoints included treatment of bleeding episodes and response to treatment. During XTEND-1, 422 bleeding episodes were reported among 159 participants; 362 were treated. Most treated bleeding episodes (74%; n = 268) occurred during the Arm B on-demand period, of which 197 (74%) were spontaneous. Seventy-five participants had no bleeding episodes in Arm A; all in Arm B had ≥ 1 bleeding episode while on-demand. Most participants (n = 107, 81%) had zero treated spontaneous bleeding episodes and rates of treated bleeding episodes in Arm A (prophylaxis) were low (median [interquartile range] overall ABR: 0.00 [0.00-1.04]). A single injection was sufficient to resolve 97% (350/362) of treated bleeding episodes, no bleeding episodes required > 3 injections, and responses to 95% of evaluable injections were rated excellent/good. Median total dose was 50.9 IU/kg per bleeding episode. Results of this analysis further demonstrated that once-weekly efanesoctocog alfa provides highly effective bleed protection and treatment of bleeding episodes in participants with severe hemophilia A. Trial Registration: NCT04161495.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Weyand AC, Meunier S, Suzuki N, et al. Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study. Am J Hematol. 2025. PMID: 39927501. doi:10.1002/ajh.27603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。